What is driving Big Pharma’s greedy, obscene behaviours we are witnessing today? It is the crack of the starting pistol once the patent clock has been set. Somewhere during the ‘Find It’ (discovery research) stage, the company registers the molecule with their local patent office. This sets a definite date for expiration of the patent protection umbrella. The patent clock is now ticking.
Every day spent on selecting a development candidate to head for the valley of death, and every day spent on ‘File It’ (applying for a license to sell), is a day lost to sales in the market in the minds of all involved – assuming, of course, that it gets to market. Given the statistic of only a 1:250 chance of a molecule getting to market, there is little appetite for spending time or money on its future. Everyone waits to see what the clinical data will look like… some five to ten years later.
The reality is of more haste and less of speed. In the frantic effort to get into the clinic as quickly as possible, Big Pharma does not take the time to select its runners carefully. The more runners there are, the thinking goes, the greater the likelihood that one of them will get through the process. As the valley becomes deeper and wider, Big Pharma has become increasingly ill-equipped to make the journey because of the emaciated state of its development and manufacturing capability, which is now predominantly in the hands of third party contract organisations.
Want to learn more about this and other Big Pharma antics?
Search Amazon.com, or Amazon.co.uk for “Find It, File It Flog It”. Take a look inside for free: click here
See also how only politicians can sort it all out: